WE HAVE A RICH PIPELINE OF INNOVATIVE NMEs IN WAVE 1 WITH TARGET LAUNCH BY END OF FY24



1. Projected timing of approvals depending on data read-outs
2. Projected approval date assumes filing on Phase 2 data
3. Currently non-pivotal Phase 2 study; assumes interim stage gates would allow for consideration of filing on Phase 2 data

✓ Stage-ups/additions since April 1, 2019
✓ Stage-ups/additions since earnings announcement October 31, 2019

Orphan potential in at least one indication
Estimated dates as of February 4, 2020
For glossary of disease abbreviations please refer to appendix.

OUR EARLY STAGE NMEs AND NEXT-GENERATION PLATFORMS IN WAVE 2 PROVIDE SUSTAINED GROWTH BEYOND FY25

TARGET APPROVAL[1] →	FY25 AND BEYOND							FY19 STAGE-UPs AND PIVOTAL DATA READOUTS
ONCOLOGY	**TAK-164** *GI malignancies*	**TAK-252** *Solid tumors*			**CELL THERAPY AND IMMUNE ENGAGERS**	**TARGETED INNATE IMMUNE MODULATION**	**NEXT-GEN CHECKPOINT MODULATORS**	✓ TAK-252 Ph1 start in solid tumors
	TAK-573 *R/R MM*	**TAK-981** *Multiple cancers*						
RARE DISEASES *Immunology Hematology Metabolic*	**TAK-079**[2] *MG, ITP*	**TAK-754** *HemA*			**GENE THERAPY**			✓ TAK-755 Ph2 start in iTTP ✓ TAK-755 Ph1/2 start in SCD
	TAK-755 *iTTP, SCD*							
NEUROSCIENCE	**TAK-341** *Parkinson's Disease*	**Orexin2R-ag** *Sleep Disorders*	**TAK-041** *CIAS NS*		**GENE THERAPY**	**OTHER PLATFORMS** *RNA Modulation Antibody Transport Vehicle*		✓ TAK-925 Ph1 start in OSA ✓ TAK-935 Ph2 start in CRPS
	TAK-418 *Kabuki Syndrome*	**TAK-653** *TRD*	**TAK-831** *CIAS NS*					
	WVE-120101 *Huntington's Disease*	**WVE-120102** *Huntington's Disease*	**TAK-935** *CRPS*					
GASTRO-ENTEROLOGY	**Kuma062** *Celiac Disease*	**TAK-101** *Celiac Disease*	**TAK-018** *Crohn's Disease (post-op and ileitis)*	**TAK-671** *Acute Pancreatitis*	**GENE THERAPY**	**MICROBIOME**	**CELL THERAPY**	
	TAK-954 *POGD*	**TAK-906** *Gastroparesis*	**TAK-951** *Nausea & vomiting*					
VACCINES	**TAK-214** *Norovirus Vaccine*	**TAK-426** *Zika Vaccine*	**TAK-021** *EV71 vaccine*					

1. Projected timing of approvals depending on data read-outs
2. TAK-079 to be developed in Rare Diseases indications myasthenia gravis (MG) and immune thrombocytopenic purpura (ITP) – FPI expected Q4 FY19

✓ Stage-ups/additions since April 1, 2019
✓ Stage-ups/additions since earnings announcement October 31, 2019

Orphan potential in at least one indication
Estimated dates as of February 4, 2020
For glossary of disease abbreviations please refer to appendix.

MAXIMIZING THE VALUE OF OUR APPROVED PROGRAMS

	PHASE 1 & 2	PHASE 3	FILED
ONCOLOGY	**ALUNBRIG®** ALK inhibitor ALK+NSCLC (JP) **NINLARO®** Proteasome inhibitor R/R MM triplet Tx (GL) **ICLUSIG®** BCR-ABL inhibitor TKI res. chronic phase CML (US) **NINLARO®** Proteasome inhibitor R/R MM doublet Tx (US, EU, JP) **ALUNBRIG®** ALK inhibitor 2L ALK+NSCLC 2nd gen TKI (GL)	**NINLARO®** Proteasome inhibitor ND MM (GL) **ICLUSIG®** BCR-ABL inhibitor FL Ph+ ALL (US) **ALUNBRIG®** ALK inhibitor 1L ALK+NSCLC (JP, US, CN) **NINLARO®** Proteasome inhibitor Maint. ND MM no SCT (GL) **NINLARO®** Proteasome inhibitor Maint. ND MM post-SCT (US, EU, CN) **ALUNBRIG®** ALK inhibitor 2L ALK+NSCLC H2H with alectinib (GL) **Cabozantinib** *Exelixis* VEGFR/RTK inhibitor 1L RCC (JP)	**Niraparib** *GlaxoSmithKline* PARP 1/2 inhibitor Ovarian cancer – maint. (JP) **ADCETRIS®** *Seattle Genetics* CD30 ADC R/R sALCL (CN) **ADCETRIS®** *Seattle Genetics* CD30 ADC R/R HL (CN) **Niraparib** *GlaxoSmithKline* PARP 1/2 inhibitor Ovarian cancer – salvage (JP) **ADCETRIS®** *Seattle Genetics* CD30 ADC 1L PTCL (EU) **Cabozantinib** *Exelixis* VEGFR/RTK inhibitor 2L RCC (JP) **Cabozantinib** *Exelixis* VEGFR/RTK inhibitor 2L HCC (JP) **ALUNBRIG®** ALK inhibitor 1L ALK+NSCLC (EU) **NINLARO®** Proteasome inhibitor Maint. ND MM post-SCT (JP)
GASTRO-ENTEROLOGY	**ENTYVIO®** α4β7 mAb Pediatric UC/CD (US)	**GATTEX** GLP-2R agonist Adult-SBS (JP) **ALOFISEL®** mesenchymal stem cells Perianal Fistulas in CD (US, JP) **GATTEX** GLP-2R agonist Pediatric-SBS (JP) **ENTYVIO®** α4β7 mAb GvHD Prophylaxis (EU, JP) **ENTYVIO®** α4β7 mAb SubQ CD (US, JP)	**ENTYVIO®** α4β7 mAb Crohn's Disease (CN) **ENTYVIO®** α4β7 mAb SubQ UC (US, EU, JP) **ENTYVIO®** α4β7 mAb SubQ CD (EU) **ENTYVIO®** α4β7 mAb Ulcerative Colitis (CN) **Vonoprazan** PCAB Prev. of L-ASA ulcers (JP)
RARE DISEASES	**NATPARA** PTH replacement Hypothyrodism (JP)	**TAKHZYRO** Anti-kallikrein mAb HAE pediatric (GL) **OBIZUR** *Ipsen* FVIII replacement CHAWI (US, EU) **VONVENDI** vWF replacement vWD Prophylaxis **TAKHZYRO** Anti-kallikrein mAb HAE (JP) **VONVENDI** vWF replacement vWD Pediatric **ADYNOVATE** Pediatric HemA (EU)	**TAKHZYRO** Anti-kallikrein mAb HAE prophylaxis (CN) **VONVENDI** vWF replacement vWD (JP)
NEUROSCIENCE		**BUCCOLAM** GABA Allosteric Modulator Status Epilepticus (JP)	
PLASMA-DERIVED THERAPIES		**CINRYZE** PD C1 Esterase inhibitor HAE prophylaxis (JP) **HYQVIA** *Halozyme* IgG 10% + Recombinant Human Hyaluronidase CIDP **HYQVIA** *Halozyme* IgG 10% + Recombinant Human Hyaluronidase Pediatric PID (US)	

FY19 STAGE-UPs

- ✓ ADCETRIS 1L PTCL filed (EU)
- ✓ NINLARO NDMM transplant filed (JP)
- ✓ Cabozantinib 2L RCC filed (JP)
- ✓ ALUNBRIG Ph3 start H2H alectinib
- ✓ ALUNBRIG Ph2 start 2nd gen TKI
- ✓ Niraparib ovarian salvage filed (JP)
- ✓ Niraparib ovarian maint. filed (JP)
- ✓ Cabozantinib 2L HCC filed (JP)
- ✓ ENTYVIO sc UC filed (received CRL)
- ✓ ENTYVIO CD filed (CN)
- ✓ ENTYVIO UC filed (CN)
- ✓ ALOFISEL Ph3 start in CPF
- ✓ Vonoprazan L-ASA ulcer prevention filed (JP)
- ✓ TAKHZYRO Ph3 start in HAE pediatric
- ✓ TAKHZYRO Ph3 start in HAE (JP)

- ✓ Stage-ups/additions since April 1, 2019
- ✓ Stage-ups since earnings announcement October 31, 2019
- Orphan Drug Designation (in any region / indication for a given asset)
- Potential for registration enabling Ph-2 study

Pipeline as of February 4, 2020; region abbreviations: GL = global (USA, Europe, Japan, China). Pipeline not all inclusive; programs also ongoing in other Therapeutic Areas
For glossary of disease abbreviations please refer to appendix